Comparison of treatment with imipenem vs. Ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: A historical cohort study

Clinical Infectious Diseases

Volumn 24, Issue 6, 1997, Pages 1131-1134

  Carmeli, Yehuda ^a   Samore, Matthew H ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; IMIPENEM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STENOTROPHOMONAS MALTOPHILIA;

EID: 0030955937     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/513652     Document Type: Article

References (12)

1. Muder RR, Yu VL, Dummer JS, Vinson C, Lumish RM. Infections caused by Pseudomonas maltophilia: expanding clinical spectrum. Arch Intern Med 1987;147:1672-4.
2. Morrison AJ Jr, Huffman KK, Wenzel RP. Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital. J Clin Microbiol 1986;24:52-5.
3. Khardori N, Elting L, Wong E, Schable B, Bodey GP. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990;12:997-1003.
4. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infections caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990;11:134-8.
5. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992;13:201-6.
6. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996;22:508-12.
7. Pankuch GA, Jacobs MR, Rittenhouse SF, Appelbaum PC. Susceptibilities of 123 strains of Xanthomonas maltophilia to eight beta-lactams (including beta-lactam-beta-lactamase inhibitor combinations) and ciprofloxacin tested by five methods. Antimicrob Agents Chemother 1994;38: 2317-22.
8. Vartivarian S, Anaissie E, Bodey G, Sprigg H, Rolston K. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy. Antimicrob Agents Chemother 1994; 38:624-7.
9. Hulisz DT, File TM. Predisposing factors and antibiotic use in nosocomial infections caused by Xanthomonas maltophilia. Infect Control Hosp Epidemiol 1992;13:489-90.
10. Kerr KG, Hawkey PM, Child JA, Norflok DR, Anderson AW. Pseudomonas maltophilia infections in neutropenic patients and the use of imipenem. Postgrad Med J 1990;66:1090.
11. Goldstein FW, Pean Y, Rosato A, Gertner J, Gutmann L, Vigil'Roc Study Group. Characterization of ceftriaxone-resistant enterobacteriaceae: a multicenter study in 26 French hospitals. J Antimicrob Chemother 1993; 32:595-603.
12. Quinn JP. Clinical significance of extended-spectrum beta-lactamases. Eur J Clin Microbiol Infect Dis 1994;13(suppl 1):39-42.